Cargando…

Liver Cirrhosis and Sarcopenia from the Viewpoint of Dysbiosis

Sarcopenia in patients with liver cirrhosis (LC) has been attracting much attention these days because of the close linkage to adverse outcomes. LC can be related to secondary sarcopenia due to protein metabolic disorders and energy metabolic disorders. LC is associated with profound alterations in...

Descripción completa

Detalles Bibliográficos
Autores principales: Nishikawa, Hiroki, Enomoto, Hirayuki, Nishiguchi, Shuhei, Iijima, Hiroko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7432211/
https://www.ncbi.nlm.nih.gov/pubmed/32722100
http://dx.doi.org/10.3390/ijms21155254
_version_ 1783571747443834880
author Nishikawa, Hiroki
Enomoto, Hirayuki
Nishiguchi, Shuhei
Iijima, Hiroko
author_facet Nishikawa, Hiroki
Enomoto, Hirayuki
Nishiguchi, Shuhei
Iijima, Hiroko
author_sort Nishikawa, Hiroki
collection PubMed
description Sarcopenia in patients with liver cirrhosis (LC) has been attracting much attention these days because of the close linkage to adverse outcomes. LC can be related to secondary sarcopenia due to protein metabolic disorders and energy metabolic disorders. LC is associated with profound alterations in gut microbiota and injuries at the different levels of defensive mechanisms of the intestinal barrier. Dysbiosis refers to a state in which the diversity of gut microbiota is decreased by decreasing the bacterial species and the number of bacteria that compose the gut microbiota. The severe disturbance of intestinal barrier in LC can result in dysbiosis, several bacterial infections, LC-related complications, and sarcopenia. Here in this review, we will summarize the current knowledge of the relationship between sarcopenia and dysbiosis in patients with LC.
format Online
Article
Text
id pubmed-7432211
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-74322112020-08-24 Liver Cirrhosis and Sarcopenia from the Viewpoint of Dysbiosis Nishikawa, Hiroki Enomoto, Hirayuki Nishiguchi, Shuhei Iijima, Hiroko Int J Mol Sci Review Sarcopenia in patients with liver cirrhosis (LC) has been attracting much attention these days because of the close linkage to adverse outcomes. LC can be related to secondary sarcopenia due to protein metabolic disorders and energy metabolic disorders. LC is associated with profound alterations in gut microbiota and injuries at the different levels of defensive mechanisms of the intestinal barrier. Dysbiosis refers to a state in which the diversity of gut microbiota is decreased by decreasing the bacterial species and the number of bacteria that compose the gut microbiota. The severe disturbance of intestinal barrier in LC can result in dysbiosis, several bacterial infections, LC-related complications, and sarcopenia. Here in this review, we will summarize the current knowledge of the relationship between sarcopenia and dysbiosis in patients with LC. MDPI 2020-07-24 /pmc/articles/PMC7432211/ /pubmed/32722100 http://dx.doi.org/10.3390/ijms21155254 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Nishikawa, Hiroki
Enomoto, Hirayuki
Nishiguchi, Shuhei
Iijima, Hiroko
Liver Cirrhosis and Sarcopenia from the Viewpoint of Dysbiosis
title Liver Cirrhosis and Sarcopenia from the Viewpoint of Dysbiosis
title_full Liver Cirrhosis and Sarcopenia from the Viewpoint of Dysbiosis
title_fullStr Liver Cirrhosis and Sarcopenia from the Viewpoint of Dysbiosis
title_full_unstemmed Liver Cirrhosis and Sarcopenia from the Viewpoint of Dysbiosis
title_short Liver Cirrhosis and Sarcopenia from the Viewpoint of Dysbiosis
title_sort liver cirrhosis and sarcopenia from the viewpoint of dysbiosis
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7432211/
https://www.ncbi.nlm.nih.gov/pubmed/32722100
http://dx.doi.org/10.3390/ijms21155254
work_keys_str_mv AT nishikawahiroki livercirrhosisandsarcopeniafromtheviewpointofdysbiosis
AT enomotohirayuki livercirrhosisandsarcopeniafromtheviewpointofdysbiosis
AT nishiguchishuhei livercirrhosisandsarcopeniafromtheviewpointofdysbiosis
AT iijimahiroko livercirrhosisandsarcopeniafromtheviewpointofdysbiosis